Joinn Laboratories(China)Co.,Ltd. (603127.SS)
CNY 17.42
(0.87%)
CNY 17.42
(0.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 396.99 Million CNY | -63.04% |
| 2022 | 1.07 Billion CNY | 92.71% |
| 2021 | 557.45 Million CNY | 76.96% |
| 2020 | 315.01 Million CNY | 76.6% |
| 2019 | 178.37 Million CNY | 64.64% |
| 2018 | 108.33 Million CNY | 41.72% |
| 2017 | 76.44 Million CNY | 47.89% |
| 2016 | 51.69 Million CNY | 5.12% |
| 2015 | 49.17 Million CNY | 0.36% |
| 2014 | 48.99 Million CNY | 119.83% |
| 2013 | 22.28 Million CNY | 131.55% |
| 2012 | 9.62 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -272.22 Million CNY | -492.28% |
| 2024 Q3 | 99.43 Million CNY | -2.97% |
| 2024 Q2 | 102.47 Million CNY | 137.65% |
| 2023 Q4 | 69.39 Million CNY | -70.72% |
| 2023 FY | 396.99 Million CNY | -63.04% |
| 2023 Q1 | 187.75 Million CNY | -57.54% |
| 2023 Q2 | -97.13 Million CNY | -151.73% |
| 2023 Q3 | 236.97 Million CNY | 343.97% |
| 2022 Q3 | 260.91 Million CNY | 6.16% |
| 2022 Q2 | 245.77 Million CNY | 96.07% |
| 2022 Q1 | 125.34 Million CNY | -59.49% |
| 2022 FY | 1.07 Billion CNY | 92.71% |
| 2022 Q4 | 442.22 Million CNY | 69.49% |
| 2021 Q1 | 93.35 Million CNY | -52.55% |
| 2021 Q3 | 94.27 Million CNY | 56.14% |
| 2021 Q4 | 309.45 Million CNY | 228.26% |
| 2021 FY | 557.45 Million CNY | 76.96% |
| 2021 Q2 | 60.37 Million CNY | -35.33% |
| 2020 Q3 | 42.61 Million CNY | -24.59% |
| 2020 Q4 | 196.72 Million CNY | 361.6% |
| 2020 FY | 315.01 Million CNY | 76.6% |
| 2020 Q1 | 19.12 Million CNY | -81.23% |
| 2020 Q2 | 56.51 Million CNY | 195.48% |
| 2019 FY | 178.37 Million CNY | 64.64% |
| 2019 Q4 | 101.88 Million CNY | 176.96% |
| 2019 Q3 | 36.78 Million CNY | 30.93% |
| 2019 Q2 | 28.09 Million CNY | 133.37% |
| 2019 Q1 | 12.03 Million CNY | -76.45% |
| 2018 Q3 | 34.78 Million CNY | 154.47% |
| 2018 Q2 | 13.66 Million CNY | 55.84% |
| 2018 Q4 | 51.11 Million CNY | 46.96% |
| 2018 Q1 | 8.77 Million CNY | -79.01% |
| 2018 FY | 108.33 Million CNY | 41.72% |
| 2017 FY | 76.44 Million CNY | 47.89% |
| 2017 Q1 | -6.91 Million CNY | -117.41% |
| 2017 Q2 | 19.1 Million CNY | 376.14% |
| 2017 Q3 | 22.47 Million CNY | 17.67% |
| 2017 Q4 | 41.78 Million CNY | 85.92% |
| 2016 Q3 | 5.15 Million CNY | 0.0% |
| 2016 Q4 | 39.72 Million CNY | 670.54% |
| 2016 FY | 51.69 Million CNY | 5.12% |
| 2015 FY | 49.17 Million CNY | 0.36% |
| 2014 FY | 48.99 Million CNY | 119.83% |
| 2013 FY | 22.28 Million CNY | 131.55% |
| 2012 FY | 9.62 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 273.29 Million CNY | -45.261% |
| WuXi AppTec Co., Ltd. | 9.6 Billion CNY | 95.868% |
| Autobio Diagnostics Co., Ltd. | 1.21 Billion CNY | 67.391% |
| Thalys Medical Technology Group Inc. | -158.57 Million CNY | 350.356% |
| Guangzhou Kingmed Diagnostics Group Co., Ltd. | 643.38 Million CNY | 38.296% |
| Chemclin Diagnostics Co., Ltd. | 147.37 Million CNY | -169.378% |